ABCP

Atezolizumab

None

None

Non small cell lung cancer (NSCLC), extensive-stage small cell lung cancer (ES-SCLC), melanoma, sarcoma, urothelial carcinoma, HCC

On May 15, 2026, the FDA approved atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test (Signatera CDx).

September 12, 2024 The FDA approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq) including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), melanoma, and alveolar soft part sarcoma (ASPS

December 9, 2022 FDA approved atezolizumab (Tecentriq) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).

October 15, 2021 The FDA approved atezolizumab (Tecentriq) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test.

July 30, 2020. The FDA approved atezolizumab (Tecentriq) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

June 5, 2020: Atezolizumab in combination with bevacizumab was approved by FDA for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

May 18, 2020 : The FDA approved atezolizumab (TECENTRIQ®) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no EGFR or ALK genomic tumor aberrations

December 3, 2019 FDA approved atezolizumab (TECENTRIQ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

March 18, 2019 FDA approved atezolizumab (TECENTRIQ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

March 8, 2019 FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer.

12/6/2018 FDA approved atezolizumab (TECENTRIQ), in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.

7/20/2018: FDA has granted Breakthrough Therapy Designation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as an initial treatment for people with advanced or metastatic hepatocellular.

4/23/2017: FDA granted accelerated approval to Tecentriq (atezolizumab) for the initial treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy. Tecentriq was previously approved for patients with locally advanced or mUC who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of receiving chemotherapy before surgery or after surgery.

October 18, 2016: FDA approved atezolizumab (TECENTRIQ) for treatment of patients with metastatic non-small cell lung carcinoma (NSCLC)whose disease has progressed during or following platinum-containing chemotherapy.

May 18, 2016 FDA gave accelerated approval to atezolizumab injection (Tecentriq) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Feb. 2015: FDA granted breakthrough designation to the immunotherapy MPDL3208A for patients with PD-L1 positive non-small cell lung cancer whose disease has progressed during or after platinum based chemotherapy and is an appropriate targeted therapy for those with an EGFR mutation-positive or ALK positive tumor.

2014: FDA granted breakthrough designation to MPDL3208A for treatment of bladder cancer.

This drug should be coded

Bevacizumab

None

None

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, this drug is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Avastin as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.

FDA has formally revoked its approval of this drug to treat breast cancer. Physicians may still prescribe it but insurers may not pay for it.
FDA approved for colorectal cancer.
FDA approved for treatment of persistent, recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
Nov. 2014: FDA approved in combination with paclitaxel, doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
In clinical trials Phase II and III for multiple myeloma
December 12, 2016: Avastin received FDA approval to be used either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

6/15/18: FDA has approved bevacizumab (Avastin) for patients with epitheli¬al ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgi¬cal resection


June 13, 2018: FDA approved bevacizumab (Avastin) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection.

December 6, 2017: FDA has granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy

This drug should be coded

Carboplatin

None

A platinum-salt alkylating agent.

This drug should be coded

Paclitaxel

None

None

Phase I (gastric) FDA approved uses on breast, ovarian, non-small cell lung cancers, and Kaposi's sarcoma. Bristol-Myers Squibb.

This drug should be coded